Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label DRF (Vumerity) in relapsing multiple sclerosis in Asia-Pacific adults
jRCT2051210115Phase 3Completed
- Sponsor
- Biogen
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of diroximel fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoints: Incidence of adverse events and serious adverse events at Week 24, Changes in clinical laboratory parameters, ECGs, and vital signs at Week 24 and 4 more. Started Dec 2021; status: completed.
02
Drugs
diroximel fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on jRCT2051210115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051210115.